A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Peer Review reports

Original Submission
11 Jul 2013	Submitted	Original manuscript
23 Aug 2013	Reviewed	Reviewer Report - Donald P Tashkin
26 Sep 2013	Reviewed	Reviewer Report - fabiano di marco
1 Oct 2013	Reviewed	Reviewer Report - Dai Lu-ming
3 Dec 2013	Author responded	Author comments - Kenneth Chapman
Resubmission - Version 2
3 Dec 2013	Submitted	Manuscript version 2
13 Dec 2013	Reviewed	Reviewer Report - fabiano di marco
17 Dec 2013	Reviewed	Reviewer Report - Donald P Tashkin
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
31 Dec 2013	Editorially accepted
17 Jan 2014	Article published	10.1186/1471-2466-14-4

Back to article page